Betamethasone + gentamicin


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: Ophth Ocular inflammation with suspected or confirmed bacterial infection As soln containing gentamicin 0.3% and betamethasone 0.1%: Instill 2 drops 3-4 times/day; acute stage: 2 drops 2 hrly. Per g oint contains gentamicin 3 mg and betamethasone 1 mg: Apply ¼ inch 3-4 times/day. Otic Otic inflammation w/ suspected or confirmed bacterial infection As soln containing gentamicin 0.3% and betamethasone 0.1%: Instill 3-4 drops 3 times/day.
Contraindications
Hypersensitivity. Ophthalmic preparations should not be used in epithelial herpes simplex keratitis (dendritic keratitis), varicella, and many other viral diseases of the cornea and conjunctiva, mycobacterial infections of the eye, trachoma, fungal diseases of ocular structures. Not to be used after removal of a corneal foreign body or in the presence of acute local viral lesions e.g. herpes, and in patients with absent or perforated tympanic membranes.
Special Precautions
Prolonged ophthalmic usage may increase the intraocular pressure. Monitor intraocular pressure if treatment lasts for ≥10 days. Prolonged use of ophthalmic corticosteroid may increase the risk of cataract formation. Increases the risk of perforation in diseases causing thinning of the cornea or sclera. Use of topical corticosteroids may lead to reactivation of disease in patients with a history of herpetic infection of the cornea. Steroid use after cataract surgery may increase risk of filtering blebs and delay healing. Prolonged use may also suppress immune response and increase risk of secondary infections. Safety and efficacy have not been established in children <8 yr. Pregnancy and lactation.
Adverse Reactions
Ophthalmic: Increased ocular pressure, increased ocular hyperemia, oedema and burning sensation. May also cause anterior uveitis or perforation of the globe. Otic: May cause ototoxicity.
ATC Classification
S03BA03 - betamethasone ; Belongs to the class of corticosteroids used in ophthalmologic and otologic preparations.
S01BA06 - betamethasone ; Belongs to the class of corticosteroids. Used in the treatment of inflammation of the eye.
C05AA05 - betamethasone ; Belongs to the class of products containing corticosteroids for topical use. Used in the treatment of hemorrhoids and anal fissures.
S01AA11 - gentamicin ; Belongs to the class of antibiotics. Used in the treatment of eye infections.
H02AB01 - betamethasone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.
D07XC01 - betamethasone ; Belongs to the class of potent (group III) corticosteroids in other combinations. Used in the treatment of dermatological diseases.
S02AA14 - gentamicin ; Belongs to the class of antiinfectives used in the treatment of ear infections.
S01CB04 - betamethasone ; Belongs to the class of corticosteroids/antiinfectives/mydriatics combinations. Used in the treatment of eye diseases.
R03BA04 - betamethasone ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids.
D07AC01 - betamethasone ; Belongs to the class of potent (group III) corticosteroids. Used in the treatment of dermatological diseases.
S03AA06 - gentamicin ; Belongs to the class of antiinfectives used in ophthalmologic and otologic preparations.
A07EA04 - betamethasone ; Belongs to the class of corticosteroids acting locally. Used in the treatment of intestinal inflammation.
R01AD06 - betamethasone ; Belongs to the class of topical corticosteroids used for prophylaxis and treatment of allergic rhinitis.
D06AX07 - gentamicin ; Belongs to the class of other topical antibiotics used in the treatment of dermatological diseases.
J01GB03 - gentamicin ; Belongs to the class of other aminoglycosides. Used in the systemic treatment of infections.
S02BA07 - betamethasone ; Belongs to the class of corticosteroids used in the treatment of inflammation of the ear.
Disclaimer: This information is independently developed by CIMS based on betamethasone + gentamicin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in